Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

WAP four-disulfide core domain protein 2 gene(WFDC2) is a target of estrogen in ovarian cancer cells.

Chen Y, Wang S, Liu T, Wu Y, Li JL, Li M.

J Ovarian Res. 2016 Feb 29;9(1):10. doi: 10.1186/s13048-015-0210-y.

2.

Current clinical application of serum biomarkers to detect ovarian cancer.

Nowak M, Janas Ł, Stachowiak G, Stetkiewicz T, Wilczyński JR.

Prz Menopauzalny. 2015 Dec;14(4):254-9. doi: 10.5114/pm.2015.55887. Epub 2015 Nov 27. Review.

3.

Serial Patterns of Ovarian Cancer Biomarkers in a Prediagnosis Longitudinal Dataset.

Blyuss O, Gentry-Maharaj A, Fourkala EO, Ryan A, Zaikin A, Menon U, Jacobs I, Timms JF.

Biomed Res Int. 2015;2015:681416. doi: 10.1155/2015/681416. Epub 2015 Dec 24.

4.

Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women.

Cho HY, Park SH, Park YH, Kim HB, Kang JB, Hong SH, Kyung MS.

J Korean Med Sci. 2015 Dec;30(12):1777-83. doi: 10.3346/jkms.2015.30.12.1777. Epub 2015 Nov 30.

5.

Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers.

Sölétormos G, Duffy MJ, Othman Abu Hassan S, Verheijen RH, Tholander B, Bast RC Jr, Gaarenstroom KN, Sturgeon CM, Bonfrer JM, Petersen PH, Troonen H, CarloTorre G, Kanty Kulpa J, Tuxen MK, Molina R.

Int J Gynecol Cancer. 2016 Jan;26(1):43-51. doi: 10.1097/IGC.0000000000000586.

6.
7.

Determination of reference intervals of serum levels of human epididymis protein 4 (HE4) in Chinese women.

Tian Y, Wang C, Cheng L, Zhang A, Liu W, Guo L, Ye H, Huang Y, Chen J, Wen X, Xing Y, Zheng G, Sun Z, Li H, Zhang P, Liu W, Chen Y, Zhang Z, Xu Y, Huo Y, Ou Q.

J Ovarian Res. 2015 Nov 9;8:72. doi: 10.1186/s13048-015-0201-z.

8.

Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.

Lane D, Matte I, Garde-Granger P, Laplante C, Carignan A, Rancourt C, Piché A.

BMC Cancer. 2015 Jul 1;15:492. doi: 10.1186/s12885-015-1511-7.

9.

Serum HE4: An Independent Prognostic Factor in Non-Small Cell Lung Cancer.

Lamy PJ, Plassot C, Pujol JL.

PLoS One. 2015 Jun 1;10(6):e0128836. doi: 10.1371/journal.pone.0128836. eCollection 2015.

10.

Comparison of specific ovarian tumor markers by elecsys analyzer 2010.

Hasanbegovic L, Alicelebic S, Sljivo N.

Acta Inform Med. 2015 Apr;23(2):86-9. doi: 10.5455/aim.2015.23.86-89. Epub 2015 Apr 14.

12.

Identification of epithelial ovarian tumor-specific aptamers.

Benedetto G, Hamp TJ, Wesselman PJ, Richardson C.

Nucleic Acid Ther. 2015 Jun;25(3):162-72. doi: 10.1089/nat.2014.0522. Epub 2015 Apr 20.

PMID:
25894736
13.

Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms: Clinical correlates.

Liao JB, Yip YY, Swisher EM, Agnew K, Hellstrom KE, Hellstrom I.

Gynecol Oncol. 2015 Jun;137(3):430-5. doi: 10.1016/j.ygyno.2015.03.044. Epub 2015 Apr 9.

PMID:
25866324
14.

Selection of DNA aptamers for ovarian cancer biomarker HE4 using CE-SELEX and high-throughput sequencing.

Eaton RM, Shallcross JA, Mael LE, Mears KS, Minkoff L, Scoville DJ, Whelan RJ.

Anal Bioanal Chem. 2015 Sep;407(23):6965-73. doi: 10.1007/s00216-015-8665-7. Epub 2015 Apr 12.

15.

Proteomics of ovarian cancer: functional insights and clinical applications.

Elzek MA, Rodland KD.

Cancer Metastasis Rev. 2015 Mar;34(1):83-96. doi: 10.1007/s10555-014-9547-8. Review.

16.

Autoantibody signature for the serologic detection of ovarian cancer.

Anderson KS, Cramer DW, Sibani S, Wallstrom G, Wong J, Park J, Qiu J, Vitonis A, LaBaer J.

J Proteome Res. 2015 Jan 2;14(1):578-86. doi: 10.1021/pr500908n. Epub 2014 Nov 17.

17.

Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women.

Fujiwara H, Suzuki M, Takeshima N, Takizawa K, Kimura E, Nakanishi T, Yamada K, Takano H, Sasaki H, Koyama K, Ochiai K.

Tumour Biol. 2015 Feb;36(2):1045-53. doi: 10.1007/s13277-014-2738-7. Epub 2014 Oct 19.

18.

Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study.

Van Calster B, Van Hoorde K, Valentin L, Testa AC, Fischerova D, Van Holsbeke C, Savelli L, Franchi D, Epstein E, Kaijser J, Van Belle V, Czekierdowski A, Guerriero S, Fruscio R, Lanzani C, Scala F, Bourne T, Timmerman D; International Ovarian Tumour Analysis Group.

BMJ. 2014 Oct 15;349:g5920. doi: 10.1136/bmj.g5920.

19.

Distinguishing benign from malignant pelvic mass utilizing an algorithm with HE4, menopausal status, and ultrasound findings.

Wilailak S, Chan KK, Chen CA, Nam JH, Ochiai K, Aw TC, Sabaratnam S, Hebbar S, Sickan J, Schodin BA, Charakorn C, Sumpaico WW.

J Gynecol Oncol. 2015 Jan;26(1):46-53. doi: 10.3802/jgo.2015.26.1.46. Epub 2014 Oct 13.

20.

Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies.

Timms JF, Arslan-Low E, Kabir M, Worthington J, Camuzeaux S, Sinclair J, Szaub J, Afrough B, Podust VN, Fourkala EO, Cubizolles M, Kronenberg F, Fung ET, Gentry-Maharaj A, Menon U, Jacobs I.

Proteomics Clin Appl. 2014 Dec;8(11-12):982-93. doi: 10.1002/prca.201400063. Epub 2014 Nov 10.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk